1: Cheung P, Amin MA, Zhang B, Lechi F, Korsgren O, Eriksson J, Odell LR, Eriksson O. [18F]MK-7246 for Positron Emission Tomography Imaging of the Beta-Cell Surface Marker GPR44. Pharmaceutics. 2023 Feb 2;15(2):499. doi: 10.3390/pharmaceutics15020499. PMID: 36839820; PMCID: PMC9962486.
2: Cheung P, Zhang B, Puuvuori E, Estrada S, Amin MA, Ye S, Korsgren O, Odell LR, Eriksson J, Eriksson O. PET Imaging of GPR44 by Antagonist [11C]MK-7246 in Pigs. Biomedicines. 2021 Apr 16;9(4):434. doi: 10.3390/biomedicines9040434. PMID: 33923731; PMCID: PMC8073488.
3: Harish B , Yadav S , Suresh S . Design and application of intramolecular vinylogous Michael reaction for the construction of 2-alkenyl indoles. Chem Commun (Camb). 2021 Jan 7;57(2):231-234. doi: 10.1039/d0cc06564a. Epub 2020 Dec 10. PMID: 33300907.
4: Richards D, Gever JR, Ford AP, Fountain SJ. Action of MK-7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation. Br J Pharmacol. 2019 Jul;176(13):2279-2291. doi: 10.1111/bph.14677. Epub 2019 May 11. PMID: 30927255; PMCID: PMC6555852.
5: Eriksson O. GPR44 as a Target for Imaging Pancreatic Beta-Cell Mass. Curr Diab Rep. 2019 Jun 27;19(8):49. doi: 10.1007/s11892-019-1164-z. PMID: 31250117; PMCID: PMC6597591.
6: Eriksson J, Roy T, Sawadjoon S, Bachmann K, Sköld C, Larhed M, Weis J, Selvaraju RK, Korsgren O, Eriksson O, Odell LR. Synthesis and preclinical evaluation of the CRTH2 antagonist [11C]MK-7246 as a novel PET tracer and potential surrogate marker for pancreatic beta-cell mass. Nucl Med Biol. 2019 Apr;71:1-10. doi: 10.1016/j.nucmedbio.2019.04.002. Epub 2019 Apr 13. PMID: 31082767.
7: Gil MA, Caniga M, Woodhouse JD, Eckman J, Lee HH, Salmon M, Naber J, Hamilton VT, Sevilla RS, Bettano K, Klappenbach J, Moy L, Correll CC, Gervais FG, Siliphaivanh P, Zhang W, Zhang-Hoover J, McLeod RL, Cicmil M. Anti-inflammatory actions of Chemoattractant Receptor-homologous molecule expressed on Th2 by the antagonist MK-7246 in a novel rat model of Alternaria alternata elicited pulmonary inflammation. Eur J Pharmacol. 2014 Nov 15;743:106-16. doi: 10.1016/j.ejphar.2014.09.021. Epub 2014 Sep 23. PMID: 25261040.
8: Mauser PJ, House A, Jones H, Correll C, Boyce C, Chapman RW. Pharmacological characterization of the late phase reduction in lung functions and correlations with microvascular leakage and lung edema in allergen-challenged Brown Norway rats. Pulm Pharmacol Ther. 2013 Dec;26(6):677-84. doi: 10.1016/j.pupt.2013.03.005. Epub 2013 Mar 19. PMID: 23523662.
9: Wang YH, Trucksis M, McElwee JJ, Wong PH, Maciolek C, Thompson CD, Prueksaritanont T, Garrett GC, Declercq R, Vets E, Willson KJ, Smith RC, Klappenbach JA, Opiteck GJ, Tsou JA, Gibson C, Laethem T, Panorchan P, Iwamoto M, Shaw PM, Wagner JA, Harrelson JC. UGT2B17 genetic polymorphisms dramatically affect the pharmacokinetics of MK-7246 in healthy subjects in a first-in-human study. Clin Pharmacol Ther. 2012 Jul;92(1):96-102. doi: 10.1038/clpt.2012.20. Epub 2012 Jun 6. PMID: 22669291; PMCID: PMC3380185.
10: Molinaro C, Bulger PG, Lee EE, Kosjek B, Lau S, Gauvreau D, Howard ME, Wallace DJ, O'Shea PD. CRTH2 antagonist MK-7246: a synthetic evolution from discovery through development. J Org Chem. 2012 Mar 2;77(5):2299-309. doi: 10.1021/jo202620r. Epub 2012 Feb 15. PMID: 22335767.
11: Simard D, Leblanc Y, Berthelette C, Zaghdane MH, Molinaro C, Wang Z, Gallant M, Lau S, Thao T, Hamel M, Stocco R, Sawyer N, Sillaots S, Gervais F, Houle R, Lévesque JF. Azaindoles as potent CRTH2 receptor antagonists. Bioorg Med Chem Lett. 2011 Jan 15;21(2):841-5. doi: 10.1016/j.bmcl.2010.11.084. Epub 2010 Nov 21. PMID: 21185722.
12: Gallant M, Beaulieu C, Berthelette C, Colucci J, Crackower MA, Dalton C, Denis D, Ducharme Y, Friesen RW, Guay D, Gervais FG, Hamel M, Houle R, Krawczyk CM, Kosjek B, Lau S, Leblanc Y, Lee EE, Levesque JF, Mellon C, Molinaro C, Mullet W, O'Neill GP, O'Shea P, Sawyer N, Sillaots S, Simard D, Slipetz D, Stocco R, Sørensen D, Truong VL, Wong E, Wu J, Zaghdane H, Wang Z. Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases. Bioorg Med Chem Lett. 2011 Jan 1;21(1):288-93. doi: 10.1016/j.bmcl.2010.11.015. Epub 2010 Nov 5. PMID: 21106375.
13: Gervais FG, Sawyer N, Stocco R, Hamel M, Krawczyk C, Sillaots S, Denis D, Wong E, Wang Z, Gallant M, Abraham WM, Slipetz D, Crackower MA, O'Neill GP. Pharmacological characterization of MK-7246, a potent and selective CRTH2 (chemoattractant receptor-homologous molecule expressed on T-helper type 2 cells) antagonist. Mol Pharmacol. 2011 Jan;79(1):69-76. doi: 10.1124/mol.110.068585. Epub 2010 Oct 13. PMID: 20943773.